Good morning, everyone, and how are you today? Did you enjoy a relaxing weekend? Well, no matter, the routine has returned. And so, as a sunny morning unfolds over the Pharmalot corporate campus, where the coffee kettle is helping us prepare another delicious cup of stimulation, the time has come to prepare for all those meetings and deadlines. We know you can relate. So what better way than to start with a few tidbits? We hope your day goes well and do stay in touch...
Alzheimer's Families Clamor For Off-Label Drug (Wall Street Journal)
Drug Data Firm Sold Raw Info To Big Pharma (The Local)
Chelsea Therapeutics Stock Plunges On Drug Study Concerns (Minyanville)
AmerisourceBergen CFO Resigns (Reuters)
Supply Of Cancer Drug May Run Out Within Weeks (New York Times)
FDA Delays Approving Novartis Menveo Vaccine For Infants (Reuters)
FDA Issues Draft Guidance To Avoid Heparin Contamination (Reuters)
Glaxo To Study Traditional Chinese Medicine (The Telegraph)
WHO Bans Pakistani Med That Caused Dozens Of Deaths (News Tribe)
FDA Commish Extends Olive Branch To Biotechs (Washington Business Journal)
A Conversation With The Head Of India's Trade Group (Pharmaphorum)
The Race To Develop A Herpes Vaccine (Boston Globe)
Spanish Debt Could Lead To Medicine Shortages (El Pais)
EDITOR'S NOTE: Please check this post for updates throughout the morning
steaming coffee thx to dleggett on flickr
1 Comment
If the QS21 STIMULON really works for the Herpes vaccine, it should be tried for other weak vaccines so that we can finally get rid of toxic adjuvants such as aluminum.